Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas

US12171783B2 · kind B2 · utility

Assignees

• The Broad Institute, Inc. · US
• Massachusetts Institute of Technology · US
• The General Hospital Corporation · US
• DANA-FARBER CANCER INSTITUTE, INC. · US

Inventors

• Mario Suva · Boston, US
• Bradley E. Bernstein · Cambridge, US
• Aviv Regev · Cambridge, US
• Mariella Filbin · Boston, US
• Itay Tirosh · Cambridge, US
• Volker Hovestadt · Boston, US

Key dates

• Filing date: Nov 13, 2018
• Grant date: Dec 24, 2024
• Expiry date: Feb 18, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/31
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The subject matter disclosed herein is generally directed to compositions and methods for treating diffuse gliomas with histone H3 lysine27-to-methionine mutations (H3K27M-gliomas). Disclosed herein are gene signatures specific for tumor cell types and compositions for treatment of H3K27M gliomas. In one embodiment, PRC1 is targeted in a treatment regimen for H3K27M-gliomas.